Acadia Pharmaceutica (ACAD)

$20.61 -0.66 (-3.10%)
Market Cap 3.51B
Revenue (ttm) 1.07B
Net Income (ttm) 391.00M
EPS (ttm) N/A
PE Ratio 29.87
Forward PE 43.85
Profit Margin 36.49%
Debt to Equity Ratio 0.00
Volume 1,553,200
Avg Vol 1,536,618
Day's Range N/A - N/A
Shares Out 170.50M
Stochastic %K 2%
Beta 0.66
Analysts Strong Sell
Price Target $31.60

Company Profile

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America. The company offers NUPLAZID (pimavanserin), a selective serotonin inverse agonist/antagonist for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 to treat the symptoms of Rett syndro...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 558 2871
Fax: 858 558 2872
Address:
12830 El Camino Real, Suite 400, San Diego, United States
Ham1198
Ham1198 Mar. 13 at 6:00 PM
$ACAD ….back to teens. Pathetic
0 · Reply
SBL71
SBL71 Mar. 13 at 3:56 PM
$ACAD teens here we come. How is everyone feeling about Q3 data? I am conflicted on to buy one final tranche of we do get to say 14-18$.
2 · Reply
Prester_John
Prester_John Mar. 13 at 2:19 PM
$ACAD Look at the volume spikes, this is a 5 day chart. All of the spikes for the last 4 days are after hours. 3:45 PM.
0 · Reply
BullMaven
BullMaven Mar. 12 at 5:02 PM
$ACAD added 500 21.22
0 · Reply
SBL71
SBL71 Mar. 11 at 8:38 PM
$ACAD are we headed back into the $14, $16-$19 again from last year...
1 · Reply
raylin
raylin Mar. 11 at 8:37 PM
$ACAD This is Fd up. Did we rehire Davis? 🤬
1 · Reply
BullMaven
BullMaven Mar. 11 at 7:05 PM
$ACAD adding 250 more
1 · Reply
JOLI2025
JOLI2025 Mar. 10 at 6:13 PM
$ACAD $ADUS $BEAT $MNDR
0 · Reply
SebNo1234
SebNo1234 Mar. 10 at 3:42 PM
$BEAT https://www.mpo-mag.com/breaking-news/heartbeam-and-mount-sinai-announce-strategic-ai-collaboration/ $ADUS $ACAD $MNDR
0 · Reply
SebNo1234
SebNo1234 Mar. 10 at 12:08 PM
$BEAT With all the news and good figures on Thursday, this place is going through the roof.🚀🚀🍀🍀👍👍 https://ir.heartbeam.com/?_gl=1*93zdi0*_ga*MTk2ODUwNzkzMy4xNzczMTQzOTQz*_ga_WW8VDXM30P*czE3NzMxNDM5NDMkbzEkZzEkdDE3NzMxNDQ0NDAkajYwJGwwJGgw $ADUS $ACAD $ABT
0 · Reply
Latest News on ACAD
Acadia Pharmaceuticals to Participate in the Stifel 2026 Virtual CNS Forum

Mar 12, 2026, 4:05 PM EDT - 3 days ago

Acadia Pharmaceuticals to Participate in the Stifel 2026 Virtual CNS Forum

Acadia Pharmaceuticals Appoints Jonathan M. Poole to its Board of Directors

Mar 3, 2026, 4:05 PM EST - 12 days ago

Acadia Pharmaceuticals Appoints Jonathan M. Poole to its Board of Directors

Acadia Pharmaceuticals Announces Plan to Request Re-Examination Following Negative CHMP Opinion for Trofinetide for the Treatment of Rett Syndrome

Mar 2, 2026, 4:05 PM EST - 13 days ago

Acadia Pharmaceuticals Announces Plan to Request Re-Examination Following Negative CHMP Opinion for Trofinetide for the Treatment of Rett Syndrome

Acadia Pharmaceuticals: Undervalued Despite Robust Revenues From Approved Drugs, With Pipeline Kicker

Feb 28, 2026, 8:58 AM EST - 15 days ago

Acadia Pharmaceuticals: Undervalued Despite Robust Revenues From Approved Drugs, With Pipeline Kicker

ACADIA Pharmaceuticals Inc. (ACAD) Q4 2025 Earnings Call Transcript

Feb 26, 2026, 1:57 AM EST - 17 days ago

ACADIA Pharmaceuticals Inc. (ACAD) Q4 2025 Earnings Call Transcript

Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operating Overview

Feb 25, 2026, 4:05 PM EST - 18 days ago

Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operating Overview

Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences

Feb 23, 2026, 4:05 PM EST - 20 days ago

Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences

Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026

Feb 4, 2026, 4:05 PM EST - 5 weeks ago

Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026

Alger Weatherbie Specialized Growth Fund Q4 2025 Winners And Laggards

Feb 3, 2026, 10:00 AM EST - 5 weeks ago

Alger Weatherbie Specialized Growth Fund Q4 2025 Winners And Laggards

AI CNS FSV GKOS KTOS MSCI NTRA

Acadia Pharmaceuticals Provides Update on Regulatory Submission for Trofinetide for the Treatment of Rett Syndrome in the European Union

Feb 2, 2026, 4:05 PM EST - 5 weeks ago

Acadia Pharmaceuticals Provides Update on Regulatory Submission for Trofinetide for the Treatment of Rett Syndrome in the European Union

ACADIA Pharmaceuticals Inc. (ACAD) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 13, 2026, 4:05 PM EST - 2 months ago

ACADIA Pharmaceuticals Inc. (ACAD) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Acadia Pharmaceuticals Provides Business and Pipeline Updates at 44th Annual J.P. Morgan Healthcare Conference

Jan 13, 2026, 9:00 AM EST - 2 months ago

Acadia Pharmaceuticals Provides Business and Pipeline Updates at 44th Annual J.P. Morgan Healthcare Conference

Acadia Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026

Dec 18, 2025, 4:05 PM EST - 3 months ago

Acadia Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026

Acadia Pharmaceuticals Announces FDA Approval of DAYBUE® STIX (trofinetide) for Oral Solution, a New Powder Formulation of Trofinetide for the Treatment of Rett Syndrome

Dec 12, 2025, 8:00 AM EST - 3 months ago

Acadia Pharmaceuticals Announces FDA Approval of DAYBUE® STIX (trofinetide) for Oral Solution, a New Powder Formulation of Trofinetide for the Treatment of Rett Syndrome

Buy Acadia Pharmaceuticals For Daybue/Nuplazid Stability And Pipeline Optionality

Dec 4, 2025, 6:26 PM EST - 3 months ago

Buy Acadia Pharmaceuticals For Daybue/Nuplazid Stability And Pipeline Optionality

ACADIA Pharmaceuticals Inc. (ACAD) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Dec 2, 2025, 1:23 PM EST - 3 months ago

ACADIA Pharmaceuticals Inc. (ACAD) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Acadia Pharmaceuticals to Participate in Citi's 2025 Global Healthcare Conference

Nov 20, 2025, 4:05 PM EST - 4 months ago

Acadia Pharmaceuticals to Participate in Citi's 2025 Global Healthcare Conference

ACADIA Pharmaceuticals Inc. (ACAD) Presents at UBS Global Healthcare Conference 2025 Transcript

Nov 10, 2025, 4:31 PM EST - 4 months ago

ACADIA Pharmaceuticals Inc. (ACAD) Presents at UBS Global Healthcare Conference 2025 Transcript

ACADIA Pharmaceuticals Inc. (ACAD) Q3 2025 Earnings Call Transcript

Nov 6, 2025, 4:36 AM EST - 4 months ago

ACADIA Pharmaceuticals Inc. (ACAD) Q3 2025 Earnings Call Transcript

Acadia Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operating Overview

Nov 5, 2025, 4:05 PM EST - 4 months ago

Acadia Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operating Overview

Halper Sadeh LLC Encourages Acadia Pharmaceuticals Inc. Shareholders to Contact the Firm to Discuss Their Rights

Oct 22, 2025, 3:41 PM EDT - 5 months ago

Halper Sadeh LLC Encourages Acadia Pharmaceuticals Inc. Shareholders to Contact the Firm to Discuss Their Rights

Acadia Pharmaceuticals to Announce Third Quarter 2025 Financial Results on November 5, 2025

Oct 15, 2025, 4:05 PM EDT - 5 months ago

Acadia Pharmaceuticals to Announce Third Quarter 2025 Financial Results on November 5, 2025

ACADIA Pharmaceuticals: Nuplazid And Daybue Are Enough To Remain Bullish

Oct 6, 2025, 7:30 AM EDT - 5 months ago

ACADIA Pharmaceuticals: Nuplazid And Daybue Are Enough To Remain Bullish

Acadia Pharmaceuticals Presents Clinical Data from Across Multiple Therapeutic Programs at the 2025 International Congress of Parkinson's Disease and Movement Disorders®

Oct 2, 2025, 9:04 AM EDT - 5 months ago

Acadia Pharmaceuticals Presents Clinical Data from Across Multiple Therapeutic Programs at the 2025 International Congress of Parkinson's Disease and Movement Disorders®

Acadia Pharma Faces Trial Setback As Prader-Willi Syndrome Trial Falls Short

Sep 24, 2025, 10:05 AM EDT - 6 months ago

Acadia Pharma Faces Trial Setback As Prader-Willi Syndrome Trial Falls Short

Acadia Pharmaceuticals' rare disease therapy fails late-stage trial

Sep 24, 2025, 7:12 AM EDT - 6 months ago

Acadia Pharmaceuticals' rare disease therapy fails late-stage trial

Acadia Pharmaceuticals Announces Phase 3 COMPASS PWS Trial of Intranasal Carbetocin (ACP-101) for Hyperphagia in Prader-Willi Syndrome Did Not Meet Primary Endpoint

Sep 24, 2025, 7:00 AM EDT - 6 months ago

Acadia Pharmaceuticals Announces Phase 3 COMPASS PWS Trial of Intranasal Carbetocin (ACP-101) for Hyperphagia in Prader-Willi Syndrome Did Not Meet Primary Endpoint

Real World Data from LOTUS Study Evaluating Long-term Efficacy and Tolerability Outcomes of DAYBUE® (trofinetide) in Patients with Rett Syndrome Published in Developmental Medicine and Child Neurology

Sep 12, 2025, 4:05 PM EDT - 6 months ago

Real World Data from LOTUS Study Evaluating Long-term Efficacy and Tolerability Outcomes of DAYBUE® (trofinetide) in Patients with Rett Syndrome Published in Developmental Medicine and Child Neurology

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sep 8, 2025, 4:05 PM EDT - 6 months ago

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ACADIA Pharmaceuticals Inc. (ACAD) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Sep 8, 2025, 4:04 PM EDT - 6 months ago

ACADIA Pharmaceuticals Inc. (ACAD) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Acadia Pharmaceuticals Appoints Konstantina Katcheves as Senior Vice President, Chief Business and Strategy Officer

Aug 25, 2025, 4:05 PM EDT - 7 months ago

Acadia Pharmaceuticals Appoints Konstantina Katcheves as Senior Vice President, Chief Business and Strategy Officer

ACADIA Pharmaceuticals Inc. (ACAD) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 3:57 AM EDT - 7 months ago

ACADIA Pharmaceuticals Inc. (ACAD) Q2 2025 Earnings Call Transcript

Acadia Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operating Overview

Aug 6, 2025, 4:05 PM EDT - 7 months ago

Acadia Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operating Overview

Acadia Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth Conference

Aug 5, 2025, 4:05 PM EDT - 7 months ago

Acadia Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth Conference

Acadia Pharmaceuticals Appoints Scott Cenci as Chief Information and Data Officer

Aug 4, 2025, 4:05 PM EDT - 7 months ago

Acadia Pharmaceuticals Appoints Scott Cenci as Chief Information and Data Officer

Acadia Pharmaceuticals: ACP-101 Read-Out Is Not Fully Priced In

Jul 28, 2025, 4:32 AM EDT - 8 months ago

Acadia Pharmaceuticals: ACP-101 Read-Out Is Not Fully Priced In

Acadia Pharmaceuticals to Announce Second Quarter Financial Results on August 6, 2025

Jul 23, 2025, 4:05 PM EDT - 8 months ago

Acadia Pharmaceuticals to Announce Second Quarter Financial Results on August 6, 2025

Acadia Pharmaceuticals Hosts Inaugural R&D Day Showcasing Pipeline and Long-Term Value Drivers

Jun 25, 2025, 8:00 AM EDT - 9 months ago

Acadia Pharmaceuticals Hosts Inaugural R&D Day Showcasing Pipeline and Long-Term Value Drivers

U.S. Court of Appeals for the Federal Circuit Affirms Prior Delaware District Court Rulings in Favor of Acadia in NUPLAZID® (pimavanserin) Composition of Matter Patent

Jun 9, 2025, 4:01 PM EDT - 9 months ago

U.S. Court of Appeals for the Federal Circuit Affirms Prior Delaware District Court Rulings in Favor of Acadia in NUPLAZID® (pimavanserin) Composition of Matter Patent

Acadia Pharmaceuticals to Host R&D Day in New York City on June 25, 2025

Jun 5, 2025, 9:05 AM EDT - 10 months ago

Acadia Pharmaceuticals to Host R&D Day in New York City on June 25, 2025

Acadia Pharmaceuticals to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

May 29, 2025, 4:05 PM EDT - 10 months ago

Acadia Pharmaceuticals to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

Acadia Pharmaceuticals Appoints Allyson McMillan-Youngblood as Senior Vice President, Rare Disease Franchise

May 27, 2025, 4:05 PM EDT - 10 months ago

Acadia Pharmaceuticals Appoints Allyson McMillan-Youngblood as Senior Vice President, Rare Disease Franchise

These Analysts Boost Their Forecasts On Acadia Pharmaceuticals

May 19, 2025, 8:25 AM EDT - 10 months ago

These Analysts Boost Their Forecasts On Acadia Pharmaceuticals

Acadia Pharmaceuticals: Another Legal Win, ACP-101 Readout Preview

May 17, 2025, 10:00 AM EDT - 10 months ago

Acadia Pharmaceuticals: Another Legal Win, ACP-101 Readout Preview

Delaware District Court Rules in Favor of Acadia in NUPLAZID® (pimavanserin) Formulation Patent Litigation

May 16, 2025, 1:43 PM EDT - 10 months ago

Delaware District Court Rules in Favor of Acadia in NUPLAZID® (pimavanserin) Formulation Patent Litigation

ACADIA Pharmaceuticals: Advancing On Several Fronts

May 13, 2025, 12:01 PM EDT - 10 months ago

ACADIA Pharmaceuticals: Advancing On Several Fronts

ACADIA Pharmaceuticals Inc. (ACAD) Q1 2025 Earnings Conference Call Transcript

May 7, 2025, 8:10 PM EDT - 11 months ago

ACADIA Pharmaceuticals Inc. (ACAD) Q1 2025 Earnings Conference Call Transcript

Acadia Pharmaceuticals Reports First Quarter 2025 Financial Results and Operating Overview

May 7, 2025, 4:05 PM EDT - 11 months ago

Acadia Pharmaceuticals Reports First Quarter 2025 Financial Results and Operating Overview

Acadia Pharmaceuticals to Participate in the BofA Securities 2025 Health Care Conference

May 5, 2025, 4:05 PM EDT - 11 months ago

Acadia Pharmaceuticals to Participate in the BofA Securities 2025 Health Care Conference

Ham1198
Ham1198 Mar. 13 at 6:00 PM
$ACAD ….back to teens. Pathetic
0 · Reply
SBL71
SBL71 Mar. 13 at 3:56 PM
$ACAD teens here we come. How is everyone feeling about Q3 data? I am conflicted on to buy one final tranche of we do get to say 14-18$.
2 · Reply
Prester_John
Prester_John Mar. 13 at 2:19 PM
$ACAD Look at the volume spikes, this is a 5 day chart. All of the spikes for the last 4 days are after hours. 3:45 PM.
0 · Reply
BullMaven
BullMaven Mar. 12 at 5:02 PM
$ACAD added 500 21.22
0 · Reply
SBL71
SBL71 Mar. 11 at 8:38 PM
$ACAD are we headed back into the $14, $16-$19 again from last year...
1 · Reply
raylin
raylin Mar. 11 at 8:37 PM
$ACAD This is Fd up. Did we rehire Davis? 🤬
1 · Reply
BullMaven
BullMaven Mar. 11 at 7:05 PM
$ACAD adding 250 more
1 · Reply
JOLI2025
JOLI2025 Mar. 10 at 6:13 PM
$ACAD $ADUS $BEAT $MNDR
0 · Reply
SebNo1234
SebNo1234 Mar. 10 at 3:42 PM
$BEAT https://www.mpo-mag.com/breaking-news/heartbeam-and-mount-sinai-announce-strategic-ai-collaboration/ $ADUS $ACAD $MNDR
0 · Reply
SebNo1234
SebNo1234 Mar. 10 at 12:08 PM
$BEAT With all the news and good figures on Thursday, this place is going through the roof.🚀🚀🍀🍀👍👍 https://ir.heartbeam.com/?_gl=1*93zdi0*_ga*MTk2ODUwNzkzMy4xNzczMTQzOTQz*_ga_WW8VDXM30P*czE3NzMxNDM5NDMkbzEkZzEkdDE3NzMxNDQ0NDAkajYwJGwwJGgw $ADUS $ACAD $ABT
0 · Reply
BullMaven
BullMaven Mar. 9 at 4:21 PM
$ACAD
0 · Reply
zeustony88
zeustony88 Mar. 6 at 8:00 PM
$ACAD I'm bullish in August-October. Wake me up when summer is over............
0 · Reply
BullMaven
BullMaven Mar. 6 at 6:16 PM
$ACAD
0 · Reply
raylin
raylin Mar. 5 at 7:13 PM
$ACAD This needs to be sold as they are consistently incompetent with trials and approvals, even with long term products that are successful in US. Europe typically follows FDA and I expected an approval with the FDA approval and track record of use.
1 · Reply
erevnon
erevnon Mar. 4 at 8:52 PM
JP Morgan maintains ACADIA Pharmaceuticals $ACAD at Overweight and raises the price target from $31 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
BobBijawklah
BobBijawklah Mar. 4 at 6:35 PM
$IBRX I have some hot Picks folks Leading or best in class. IBRX below 9 is a buy. $SMMT will be the next iteration of pdl1 surpassing keytruda in all indications PT $35 PDUFA Nov 2026. $DNLI hunter syndrome PDUFA April 2026 PT 30 .$ACAD nuplazid and dayblue 1 billion in revenue . Remlifanserin data due out later this year. Potential revenue of Remlifanserin 4 billion. PT 35. $MLTX Merck already put a 41 dollar offer which was turned down. Trades at 18 per share PT 40.
2 · Reply
KindraJohnson216
KindraJohnson216 Mar. 4 at 6:05 PM
$ACAD biotech midcap forming base if buyers defend level watch breakout
0 · Reply
ZacksResearch
ZacksResearch Mar. 4 at 1:04 PM
$ACAD hits a regulatory wall in the EU ⚠️ CHMP rejected trofinetide for Rett syndrome, delaying potential approval — even after positive LAVENDER study results. Now the company plans a re-examination, but timelines just got pushed out. Is this a temporary setback or a bigger red flag? Get the full regulatory breakdown here 👉 https://www.zacks.com/stock/news/2878442/acad-plans-re-examination-after-chmp-rejects-rett-syndrome-drug-in-eu?cid=sm-stocktwits-2-2878442-teaser-35847&ADID=SYND_STOCKTWITS_TWEET_2_2878442_TEASER_35847
0 · Reply
ZacksResearch
ZacksResearch Mar. 4 at 12:04 PM
$ACAD faces EU setback, but is the long-term growth story intact? 🤔 Despite the CHMP's negative opinion on trofinetide, Acadia is banking on U.S. sales of Nuplazid and Daybue, projecting $1.7 billion by 2028, with Nuplazid contributing $1 billion and Daybue $700 million. Nuplazid alone brings in $1 billion, protected against generics until 2038, while Daybue plans to expand its franchise with a new formulation in 2026. Opportunity assessment here 👉 https://www.zacks.com/stock/news/2878442/acad-plans-re-examination-after-chmp-rejects-rett-syndrome-drug-in-eu?cid=sm-stocktwits-2-2878442-body-35846&ADID=SYND_STOCKTWITS_TWEET_2_2878442_BODY_35846
0 · Reply
SuperGreenToday
SuperGreenToday Mar. 3 at 12:29 AM
$ACAD Share Price: $22.81 Contract Selected: Sep 18, 2026 $22.0 Calls Buy Zone: $2.25 – $2.78 Target Zone: $4.26 – $5.21 Potential Upside: 79% ROI Time to Expiration: 199 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
BullMaven
BullMaven Mar. 3 at 12:21 AM
$ACAD For DAYBUE, ACADIA is guiding $460M–$490M this year (~20% growth), is launching the new DAYBUE STIX formulation to broaden uptake (estimated ~400 incremental patients by 2028), and plans to seek reexamination after a CHMP negative opinion in Europe by emphasizing clinical meaningfulness and patient experience.
0 · Reply
BullMaven
BullMaven Mar. 3 at 12:20 AM
$ACAD Remlifanserin (ACP-204): Phase II Alzheimer’s disease psychosis readout expected Aug.–Oct. ACADIA discussed its next-generation 5-HT2A inverse agonist, remlifanserin (also referred to as ACP-204), with top-line Phase II data expected in a narrowed window of August to October.
0 · Reply